MDGN

AcronymDefinition
MDGNMedical and Dental Guidance Notes (UK)
References in periodicals archive ?
63, 445 pence per Common Share, being the MDGN closing price on the Reference Date as reported on NYSE MKT.
NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump[TM], a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced the presentation of preliminary data from its ongoing Phase IIa clinical trial in Israel with EPODURE[TM] Biopumps to treat anemia in patients on dialysis with end-stage renal disease ("ESRD"), by sustained delivery of erythropoietin ("EPO").
NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the Company will be presenting a poster at the upcoming American Society of Nephrology's Kidney Week 2012, taking place from October 30 to November 4 in San Diego.
NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company") today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC").
NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump[TM], a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE[TM] in patients with hepatitis C.
NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of Biopump[TM], a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced financial results for three and six months ended June 30, 2012, and the filing with the U.
NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump[TM], a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the launch of its Phase IIa clinical trial in Israel of EPODURE[TM] Biopumps to treat anemia in patients with end-stage renal disease ("ESRD" or "kidney failure") on dialysis, through the sustained delivery of erythropoietin ("EPO").